Trial Profile
A Pharmacokinetic and Phase 2 Study of Sunitinib Malate in Recurrent Malignant Gliomas.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 03 Mar 2016
Price :
$35
*
At a glance
- Drugs Sunitinib (Primary)
- Indications Astrocytoma; Glioblastoma; Glioma
- Focus Adverse reactions; Pharmacokinetics; Therapeutic Use
- 29 Jan 2016 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
- 21 Jul 2009 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 09 Aug 2007 New trial record.